Comparative Pharmacology
Head-to-head clinical analysis: NEBCIN versus NEOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEBCIN versus NEOMYCIN SULFATE.
NEBCIN vs NEOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death by disrupting the cytoplasmic membrane.
3-6 mg/kg/day IV in 2-3 divided doses every 8-12 hours; adjust based on serum levels and renal function.
1-2 g orally 4 times daily (8-16 g/day) for hepatic encephalopathy or intraluminal infection; 0.5-1 g orally 4 times daily for preoperative bowel preparation.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in patients with normal renal function. Prolonged to 24-48 hours in anuria. Clinical context: Dosing interval adjustment required in renal impairment to avoid toxicity.
2-3 hours (normal renal function); prolonged to 20-60 hours in anuria
Renal excretion of unchanged drug accounts for >90% of elimination. Approximately 10% is excreted in bile.
Renal (glomerular filtration) >90% unchanged; small amount biliary/fecal (<3%)
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic